AMG 994
Alternative Names: AMG-994Latest Information Update: 28 May 2024
At a glance
- Originator Amgen
- Developer Amgen; BeiGene
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium (IV, Infusion)
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV, Infusion)